Shandong-based biopharmaceutical company Boan Biotech (HK:06955) has released its fourth Environmental, Social and Governance Report, detailing 2025 performance across innovation, compliance, environment and workforce management.
Boan Biotech maintained all four ISO management systems—ISO 9001 (quality), ISO 14001 (environment), ISO 45001 (occupational health & safety) and ISO 50001 (energy)—following annual surveillance audits, underpinning a Board-supervised ESG framework that includes an ESG Committee and an ESG Working Group. No breaches of anti-corruption regulations or concluded legal cases were reported.
Innovation momentum remained strong: five commercial products are on the market, two of which—Boyoujing® and Boyouping®—passed China’s GMP inspection in 2025. The company secured 50 new patents (total pending: 43) and held 90 valid trademarks worldwide. Core R&D is driven by four proprietary technology platforms covering fully-human antibodies, multispecific antibodies, ADCs and AI-enabled drug discovery.
Environmental data show total Scope 1 and 2 greenhouse-gas emissions of 13,468.21 tCO₂e, sourced mainly from purchased electricity and industrial steam. Indirect energy consumption reached 30,492.66 MWh, water use was 159,279 m³ and hazardous waste generation stood at 32.45 t—below the internal ceiling of 35 t. Non-hazardous waste amounted to 3.66 t, and all VOC emissions met regulatory limits.
The green strategy earned multiple regional honours, including “Shandong Green Factory” and “2025 Yantai Zero-Waste Factory”. Operational upgrades—such as demand-based steam scheduling—cut annual utility costs by RMB3.70 million.
Human-capital metrics underline a 696-strong workforce, 65 % of whom are women. Turnover was 11 % overall, with no work-related fatalities or lost-time injuries recorded. Training averaged 76.9 hours per employee for staff below managerial level, supported by the “Action Learning Empowerment Camp” and the “Boan Lecture Series”.
Supply-chain oversight spans 2,077 suppliers (1,994 domestic; 83 overseas). All contracts contain anti-bribery clauses, and green-procurement rules favour energy-efficient equipment and recyclable packaging.
Community investment continued through the Boyounuo® Patient Relief Project, executed with the Beijing Health Alliance Charitable Foundation via donations of bevacizumab injections to economically disadvantaged patients.
The Board approved the ESG report on 30 March 2026 and reaffirmed long-term goals of lowering emissions intensity, keeping hazardous waste below 35 t and expanding climate-risk management as data systems mature.
Comments